CoChat

Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial

Mack, Michael J., Abraham, William T., Lindenfeld, JoAnn, Bolling, Steven F., Feldman, Ted E., Grayburn, Paul A., Kapadia, Samir R., McCarthy, Patrick M., Lim, D. Scott, Udelson, James E., Zile, Michael R., Gammie, James S., Gillinov, A. Marc, Glower, Donald D., Heimansohn, David A., Suri, Rakesh M., Ellis, Jeffrey T., Shu, Yu, Kar, Saibal, Weissman, Neil J., Stone, Gregg W. · 2018 · American Heart Journal
Cited by 110

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background Patients with heart failure (HF) and symptomatic secondary mitral regurgitation (SMR) have a poor prognosis, with morbidity and mortality directly correlated with MR severity. Correction of isolated SMR with surgery is not well established in this population, and medical management remains the preferred approach in most patients. The Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial was designed to determine whether transcatheter mitral valve (MV) repair with the MitraClip device is safe and effective in patients with symptomatic HF and clinically significant SMR. Study design The COAPT trial is a prospective, randomized, parallel‐controlled, open‐label multicenter study of the MitraClip device for the treatment of moderate‐to‐severe (3+) or severe (4+) SMR (as verified by an independent echocardiographic core laboratory) in patients with New York Heart Association class II‐IVa HF despite treatment with maximally tolerated guideline‐directed medical therapy (GDMT) who have been determined by the site's local heart team as not appropriate for MV surgery. A total of 614 eligible subjects were randomized in a 1:1 ratio to MV repair with the MitraClip plus GDMT versus GDMT alone. The primary effectiveness end point is recurrent HF hospitalizations through 24 months, analyzed when the last subject completes 12‐month follow‐up, powered to demonstrate superiority of MitraClip therapy. The primary safety end point is a composite of device‐related complications at 12 months compared to a performance goal. Follow‐up is ongoing, and the principal results are expected in late 2018. Conclusions HF patients with clinically significant SMR who continue to be symptomatic despite optimal GDMT have limited treatment options and a poor prognosis. The randomized COAPT trial was designed to determine the safety and effectiveness of transcatheter MV repair with the MitraClip in symptomatic HF patients with moderate‐to‐severe or severe SMR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2018.07.021

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 110

Metadata

Authors
Mack, M. J., Abraham, W. T., Lindenfeld, J., Bolling, S. F., Feldman, T. E., Grayburn, P. A., Kapadia, S. R., McCarthy, P. M., Lim, D. S., Udelson, J. E., Zile, M. R., Gammie, J. S., Gillinov, A. M., Glower, D. D., Heimansohn, D. A., Suri, R. M., Ellis, J. T., Shu, Y., Kar, S., Weissman, N. J., & Stone, G. W.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2018-11
Volume
205
Pages
1-11
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2886738924
Cited by
110
References
4
FWCI
9.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.